WAKE-UP试验中阿替普酶静脉溶栓对血管闭塞患者的效果
该研究基于多中心随机安慰剂对照WAKE-UP试验的子样本,纳入185例MRI弥散加权成像可见急性缺血灶但FLAIR无显著高信号的未知发病时间卒中患者,分析MRI引导下阿替普酶静脉溶栓在伴血管闭塞患者中的疗效。结果显示,任何血管闭塞患者中阿替普酶组90天良好结局(mRS 0-1)为31.9%,安慰剂组为19.8%(aOR 2.04,95%CI 1.00-4.18);大血管闭塞亚组中分别为30.2%和15.9%(aOR 2.08,95%CI 0.71-6.10)。作者认为该亚组分析提示MRI引导溶栓的获益不依赖于血管闭塞状态。
要点
- 任何血管闭塞患者中,阿替普酶组90天良好结局31.9%,安慰剂组19.8%(aOR 2.04,95%CI 1.00-4.18)。
- 大血管闭塞亚组中,阿替普酶组良好结局30.2%,安慰剂组15.9%(aOR 2.08,95%CI 0.71-6.10)。
- 血管状态与治疗效应无交互作用(任何血管闭塞与血管通畅组p=0.56;大血管闭塞与无大血管闭塞组p=0.69)。
核心结论
- WAKE-UP研究未针对亚组人群疗效检验效能,但该亚组分析提示MRI引导溶栓对未知发病时间缺血性卒中患者的获益不依赖于血管闭塞状态。
研究设计与样本
- 多中心、随机、安慰剂对照WAKE-UP试验的子样本分析,纳入185例MRI弥散加权成像可见急性缺血灶但FLAIR无显著高信号的未知发病时间卒中患者,随机接受静脉阿替普酶或安慰剂治疗。
主要发现
- 任何血管闭塞患者中,阿替普酶组94例中30例(31.9%)获得90天良好结局(mRS 0-1),安慰剂组91例中18例(19.8%)获得良好结局(aOR 2.04,95%CI 1.00-4.18)。
- 大血管闭塞亚组中,阿替普酶组53例中16例(30.2%)获得良好结局,安慰剂组44例中7例(15.9%)获得良好结局(aOR 2.08,95%CI 0.71-6.10)。
- 任何血管闭塞与血管通畅患者之间治疗效应无异质性(p=0.56),大血管闭塞与无大血管闭塞患者之间亦无异质性(p=0.69)。
关键数值与推荐
- 主要终点为卒中后90天改良Rankin量表评分0-1分的良好结局。
- 大血管闭塞定义为颈内动脉、大脑中动脉主干或两者组合的闭塞。
临床怎么用
- 原文未据此给出推荐。
局限性
- WAKE-UP研究未针对亚组人群疗效检验效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Data from randomized trials on the treatment effect of pure thrombolysis in patients with vessel occlusion are lacking. We examined data from a corresponding subsample of patients from the multicenter, randomized, placebo-controlled WAKE-UP trial to determine whether MRI-guided IV thrombolysis with alteplase in unknown-onset ischemic stroke benefits patients presenting with vessel occlusion. METHODS: Patients with an acute ischemic lesion visible on MRI diffusion-weighted imaging but no marked parenchymal hyperintensity on fluid-attenuated inversion recovery images were randomized to treatment with IV alteplase or placebo. The primary end point was a favorable outcome defined by a modified Rankin Scale score of 0-1 at 90 days after stroke. We investigated the interaction between vessel status and treatment effect using an unconditional logistic regression model. Treatment effects (adjusted odds ratio [aOR]) and their 95% CI were compared in patients with and without any vessel occlusion (AVO) and large vessel occlusion (LVO). RESULTS: 185 patients (mean age 64.5 years, 46% female, median NIH Stroke Scale score 9, median time between last seen well and MRI 10.26 hours) received treatment and presented with an occlusion. 98 (20%) had LVO (defined as occlusion of the internal carotid artery, middle cerebral artery trunk, or combination). A favorable outcome was observed in 30 of 94 patients with AVO (31.9%) in the alteplase group and in 18 of 91 (19.8%) in the placebo group (aOR 2.04, 95% CI 1.00-4.18). In the subgroup of patients with LVO, a favorable outcome was observed in 16 of 53 (30.2%) in the alteplase group and in 7 of 44 (15.9%) in the placebo group (aOR 2.08, 95% CI 0.71-6.10). Treatment with alteplase was associated with higher odds of favorable outcomes with no heterogeneity of treatment effect between patients with AVO and patent vessel (p = 0.56), or between patients with and without LVO (p = 0.69). DISCUSSION: Although the WAKE-UP study was not powered to demonstrate treatment efficacy in patient subpopulations, this subgroup analysis points to a benefit of MRI-guided thrombolysis in patients with unknown-onset ischemic stroke, independent of vessel occlusion. CLINICAL TRIAL REGISTRATION: Registered at ClinicalTrials.gov with unique identifier NCT01525290 (clinicaltrials.gov/study/NCT01525290). The study was first posted on February 2, 2012; the first patient was enrolled on September 24, 2012. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with unknown-onset ischemic stroke with AVO, MRI-guided treatment with IV tissue plasminogen activator improves outcomes.
引用
- Galinovic I, Fiebach JB, Boutitie F, et al. Effect of IV Thrombolysis With Alteplase in Patients With Vessel Occlusion in the WAKE-UP Trial. Neurology. 2024. PMID: 39705631. doi:10.1212/WNL.0000000000209871
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。